We had the great pleasure of meeting with Andrew Blumenfeld (Director, Headache, The Neurology Center of Southern California, Carlsbad, CA, USA) to discuss the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine.
The abstract ‘Combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine’ was presented at the American Headache Society (AHS) Virtual Annual Scientific Meeting 2021, 3-6 June 2021.
- What is the rationale for the combination use of onabotulinumtoxinA and CGRP mAbs in the treatment of chronic migraine? (0:17)
- Could you tell us a little about the aims, method and findings of the longitudinal chart review you conducted? (1:56)
- What did we learn in terms of safety and tolerability? (9:18)
Disclosures: Andrew Blumenfeld is on the advisory board for Allergan, Abbvie, Aeon, Alder, Amgen, Axsome, Biohaven, Impel, Lundbeck, Lilly, Novartis, Revance, Teva, Theranica, and Zosano Pharma; a speaker for Allergan, Abbvie, Amgen, Biohaven, Lundbeck, Lilly, and Teva; a consultant for Allergan, Abbvie, Alder, Amgen, Biohaven, Lilly, Lundbeck, Novartis, Teva, and Theranica; receives grant support from Allergan and Amgen; and is a contributing author for Allergan, Abbvie, Amgen, Novartis, Teva, Lilly, and Biohaven.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AHS Virtual Annual Scientific Meeting 2021
Share this Video
Related Videos In Headache Disorders
Raquel Gil-Gouveia, EAN 2022: Highlights in headache and migraine – Treatment advances, strategies for prevention, Anti-CGRP use in migraine, COVID-19
Headache is one of the most common nervous system disorders. In an interview with touchNEUROLOGY, Dr Raquel Gil-Gouveia (Hospital da Luz, Lisbon, Portugal) summarizes the ePoster session she chaired at EAN 2022, ranging from topics such as how COVID-19 has impacted on young people with headaches, the potential of new treatments such as eptinezumab and […]
Stewart Tepper, AAN 2022: Limitations of current treatments for acute migraine
The limitations of the current treatment of acute migraine are said to be patient variability and migraine attack variability. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) discusses the limitations of current treatments for acute migraine and how new treatments overcome these. The abstract entitled ‘Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the […]
Stewart Tepper, AAN 2022: Phase III MOMENTUM trial results, investigating meloxicam-rizatriptan for the acute treatment of migraine
Meloxicam-Rizatriptan (AXS-07) is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine which combines meloxicam and rizatriptan for the acute treatment of migraine. Prof. Stewart Tepper (Dartmouth-Hitchcock Medical Centre, Lebanon, NH, USA) joins us to discuss the phase III MOMENTUM trial aims and design, and the efficacy, safety and tolerability findings of Meloxicam-Rizatriptan for the acute […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!